Publications list for Dr Kellie Charles

2013 | 2012 | 2011 | 2010 | 2009 | 2008


  • Guthrie, G., Charles, K., Roxburgh, C., Horgan, P., McMillan, D., Clarke, S. (2013), The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Critical Reviews in Oncology/Hematology. 88(1), 218-230. [Abstract]
  • Elens, L., Nieuweboer, A., Clarke, S., Charles, K., de Graan, A., Haufroid, V., van Gelder, T., Mathijssen, R., van Schaik, R. (2013), Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenetics and Genomics. 23(3), 148-155. [Abstract]
  • Elens, L., Nieuweboer, A., Clarke, S., Charles, K., de Graan, A., Haufroid, V., Mathijssen, R., van Schaik, R. (2013), CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics. 14(2), 137-149. [Abstract]


  • Chua, W., Clarke, S., Charles, K. (2012), Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Supportive Care in Cancer. 20(8), 1869-1874. [Abstract]


  • Chua, W., Kho, P., Moore, M., Charles, K., Clarke, S. (2011), Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Critical reviews in oncology/hematology. 79(3), 224-50. [Abstract]
  • Clarke, S., Chua, W., Moore, M., Kao, S., Phan, V., Tan, C., Charles, K., McMillan, D. (2011), Use of inflammatory markers to guide cancer treatment. Clinical Pharmacology and Therapeutics. 90(3), 475-478. [Abstract]
  • Chua, W., Charles, K., Baracos, V., Clarke, S. (2011), Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. British Journal of Cancer. 104(8), 1288-1295. [Abstract]


  • Moore, M., Chua, W., Charles, K., Clarke, S. (2010), Inflammation and cancer: causes and consequences. Clinical Pharmacology and Therapeutics. 87(4), 504-508. [Abstract]


  • Chua, W., Moore, M., Charles, K., Clarke, S. (2009), Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Current Opinion in Molecular Therapeutics. 11(6), 611-622. [Abstract]
  • Charles, K., Kulbe, H., Soper, R., Escorcio-Correia, M., Lawrence, T., Schultheis, A., Chakravarty, P., Thompson, R., Kollias, G., Smyth, J., Balkwill, F., Hagemann, T. (2009), The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. Journal of Clinical Investigation. 119(10), 3011-3023. [Abstract]


  • Brown, E., Charles, K., Hoare, S., Rye, R., Jodrell, D., Aird, R., Vora, R., Prabhakar, U., Nakada, M., Corringham, R., DeWitte, M., Sturgeon, C., Propper, D., Balkwill, F., Smyth, J. (2008), A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Annals of Oncology. 19(7), 1340-1346. [Abstract]
  • Hagemann, T., Lawrence, T., McNeish, I., Charles, K., Kulbe, H., Thompson, R., Robinson, S., Balkwill, F. (2008), "Re-educating" tumor-associated macrophages by targeting NF-kappaB. The Journal of Experimental Medicine. 205(6), 1261-1268. [Abstract]
  • Morgan, E., Goralski, K., Piquette-Miller, M., Renton, K., Robertson, G., Chaluvadi, M., Charles, K., Clarke, S., Kacevska, M., Liddle, C., Richardson, T., Sharma, R., Sinal, C. (2008), Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metabolism and Disposition. 36(2), 205-216. [Abstract]